To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 29, 2019

Today's Rundown

Featured Story

Iannone walks out on troubled Immunomedics a year after taking CMO job

Last April, Immunomedics scored a former AstraZeneca cancer executive as its research lead; one year down the line, and Robert Iannone, M.D., is moving on as the biotech attempts to rebound from an FDA rejection and the loss of its CEO.

Top Stories

Biopharma converts 24% of NMEs to drugs, with Celgene bringing up the rear: report

Though biopharmas seem to be using their R&D dollars more effectively, they are only converting 24% of new molecular entities to approved drugs, SVB Leerink found in a five-year analysis of eight biopharma companies.

Regeneron bags Calixar tech to support antibody discovery effort

Regeneron has bought the right to use Calixar’s membrane protein technology to discover antibodies against an undisclosed target. The deal gives Regeneron access to technology designed to conserve the functional and structural integrity of targets.

[Sponsored] Emerging Biotechs are Here to Stay; CROs Models Will Permanently Change

The prominence of emerging biotech looms large on the drug development landscape. CROs continue to adjust their core competencies and cultural mindset to tailor services for specific biotech needs.

Bicycle files for $86M IPO to fund trials of novel drug conjugates

Bicycle Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The British biotech wants the money to prepare for phase 2 and 3 clinical trials of its lead anticancer candidate, BT1718.

New phase 3 data paint fuller picture for Horizon's teprotumumab: AACE

Horizon Pharma presented new data from a phase 3 study of its inflammatory eye drug teprotumumab that dig deeper into how fast the drug works and how it stacks up against the current treatment: eye surgery.

FBI raids uBiome’s San Francisco HQ over insurance billing practices: reports

The FBI has raided the San Francisco headquarters of sequencing-based test provider uBiome, as part of a snowballing investigation into the company’s billing practices by law enforcement agencies, state regulators and insurance companies. The Friday morning search was first reported by The Wall Street Journal.

Resources

[Whitepaper] Agile Competitive Intelligence: A 3-Step Mobile Research Strategy

What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve?

[Whitepaper] Now Companies Can Move Validated, Mission Critical Apps To The Cloud

Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment.

[Whitepaper] How the Internet of Things Creates Smarter Labs

Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”.

[Whitepaper] Personalized Test for Treatment Prediction in Depression

Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy.

[Whitepaper] Observed Impact of Medication Price Transparency on Patients and Practices

Prescription price transparency technology is here – but is it making a difference? Find out HERE.

[Whitepaper] Redefining Your Value to Win Empowered Patients: Six Steps to Success

Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver?

[Whitepaper] Key Life Sciences Trends, 2019 and Beyond

The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries.

[Whitepaper] The New World of Allosteric Modulation: Another Shot on Goal

Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more.

[Whitepaper] Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development

Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate.

[Whitepaper] Workbench for Biomarker and Translational Research

Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma.

[Whitepaper] Meet Our Uncle: 12 Protein Stability Applications on One Platform

Download this whitepaper to learn more!

[Whitepaper] Flow Chemistry For Modern API Development & Manufacturing

Is Flow Chemistry right for your API Development?

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events